Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice

Figure 1 Design of the experiment. The db/db diabetic mice were randomized into vehicle and empagliflozin groups. Heterozygous non-diabetic db/+ mice were included as controls. The studied drug or vehicle was administered by gavage once per day from 8 to 16 wk of age. Procedure 1 at wk 8: Weight measurement, body composition assessment, blood and urine sampling. Procedure 2 at wk 12: Weight measurement, body composition assessment, blood sampling. Procedure 3 at wk 16: Weight measurement, body composition assessment, blood and urine sampling, sacrifice and kidney sampling. EMPA: Empagliflozin.